Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupiyichang pill vs pinaverium bromide in diarrhea-predominant irritable bowel syndrome
ChiCTR-IPR-16008365Phase 4Completed
- Sponsor
- Capital Medical University
- Start
- Oct 2012
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Bupiyichang pill and pinaverium in Diarrhea-predominant irritable bowel syndrome (IBS-D) (3 arms), sponsored by Capital Medical University. Primary endpoints: Abdominal pain severity, Diarrhea frequency and 1 more. Started Oct 2012; status: completed.
02
Drugs
Bupiyichang pillpinaverium
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on ChiCTR-IPR-16008365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008365.